Cann Pharmaceutical Australia

Cann Pharmaceutical Australia is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceutical-grade medicinal cannabis therapies. As the Australian arm of the Israel-based Better Holdings (Cann Pharmaceutical Ltd), the company utilizes over a decade of Israeli R&D and a proprietary genetic library to produce standardized cannabinoid treatments. Its lead candidate, EP1, is a CBD-enriched cannabis oil currently undergoing Phase 2 clinical trials for pediatric refractory epilepsy. Additionally, the company is collaborating with Arovella Therapeutics to develop ALA-021, an oro-mucosal spray for indications including drug-resistant epilepsy, melanoma, and motion sickness. Cann Pharmaceutical Australia aims to provide clinically validated alternatives to traditional cannabis products, targeting significant unmet needs in neurology and oncology.